Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
Key Highlights
- ➤September 2026 Phase 2a CY200 protocol submitted to UK medicines regulator
- ➤CY200 gained FDA Orphan Drug Designation for Complex Regional Pain Syndrome
- ➤Ensysce acquired Cy Biopharma in August 2026, making CY200 a pipeline priority
- ➤James Morrison expanded Middle East investor and strategic-partner outreach in Dubai
Expert Statements
James Morrison, President of Ensysce Biosciences
“We are entering an important stage in Ensysce's evolution, and expanding our relationships with sophisticated global investors and strategic partners is a key priority.”
James Morrison, President of Ensysce Biosciences
“The UAE has rapidly developed into a major international center for capital, healthcare innovation and life sciences, making this an ideal opportunity to tell the Ensysce story and introduce the Company to a broader global investment community.”
James Morrison, President of Ensysce Biosciences
“Patients with CRPS have very few options, and CY200 is designed to address that need.”
James Morrison, President of Ensysce Biosciences
“Our objective in the UAE was to meet investors and potential partners who take a long-term view of drug development and who understand the opportunity in differentiated clinical-stage assets.”
SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS") today announced that James Morrison, President of Ensysce Biosciences, participated in the Family Office Summit, Dubai, on October 15, 2026.
The visit was a central component of Ensysce's expanding global investor and strategic outreach initiative. At the summit, a private gathering for the family office sector, Mr. Morrison met family offices from across the Middle East to introduce the Company and its focus on severe chronic pain, and to begin long-term relationships with investors and potential partners in the region.
Get started
Create a free account to read the full story.